Eliciting Immune Responses Using Recombinant MVA Viruses Expressing HIV Env, Gag and Pol Anitgens

Methods for eliciting beneficial immune responses against HIV by administering to a subject a recombinant MVA virus expressing HIV env, gag, and pol antigens are described. The recombinant MVA is administered at least three times and, in certain embodiments, is administered to a patient that has not been treated with a DNA vaccine directed against HIV (i.e., has not been treated with a nucleic acid molecule encoding one or more HIV antigens). The methods can elicit production IgA antibodies directed against HIV in rectal secretions of a treated subject.

Patents:
WO 2,011,047,031   [MORE INFO]

Inventor(s): ROBINSON HARRIET L [US]; MOSS BERNARD [US]; WYATT LINDA S [US]; AMARA RAMA R [US]

Type of Offer: Licensing



Next Patent »
« More Biotech Patents

Share on      


CrowdSell Your Patent